What Metamizol Stada Treats: Main Uses and Benefits

The medicine is applied across domains where additional symptomatic support is needed and is relevant when symptoms create noticeable interference with comfort and function. Metamizol (Dipyrone) is commonly used to help treat severe pain and fever that cannot be controlled with other medications, confirming its role across multiple therapeutic domains.

The medication is commonly used across conditions presenting with acute episodes and significant symptomatic burden. It is relevant in conditions characterized by periods of heightened symptoms, including those related to acute pain, spasm-related symptoms, and unstable fever states.

“The medication provides supportive relief when symptoms interfere with routine activities, assisting with the complex symptom cluster associated with spasm.”

The medication is considered relevant in clinical settings that involve acute or unstable symptom patterns, assisting with the relief of symptoms related to physical discomfort and systemic imbalance. The core benefit contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Quick Fact: Relief for Visceral Spasm

Metamizol Stada is considered relevant for easing symptoms related to heightened physiological activity, especially in spasm-related conditions, which may assist with symptomatic relief during colic attacks.

Who Can and Cannot Use Metamizol Stada?

The eligibility for Metamizol Stada (Sodium Metamizole) is strictly defined by regulatory authorities based on contraindications and population restrictions.

Absolute Contraindications

The medicine must not be used in patients with specific conditions, including a history of agranulocytosis caused by metamizole or other pyrazolones, known impaired bone marrow function, or established diseases of the haematopoietic system. Use is also contraindicated in individuals with analgesic asthma, acute intermittent hepatic porphyria, or glucose-6-phosphate dehydrogenase deficiency.

Age and Physiological Restrictions

Metamizol Stada is absolutely contraindicated in infants below the age of 3 months or weighing less than 5 kg. For children and adolescents (3 months to 14 years), use is established but requires dosage determined by body weight, while use is standard for those ge 15 years. The medicine is contraindicated during the third trimester of pregnancy and is not recommended during the first six months or while breastfeeding (lactation).

Conditional Use Populations

Use is not recommended or requires strict caution in patients with impaired renal function (kidneys), impaired hepatic function (liver), or pre-existing circulatory instability (e.g., hypotension). Older adults may require special consideration due to potential delayed excretion of the drug’s metabolites.

Interactions with other medicines and products

This section describes the official interaction information for Sodium Metamizole (Metamizol Stada) as documented in government regulatory sources.

Interaction Scope

Interaction Classifications (High-Level)

Official interaction statements:

• Co-administration with Chlorpromazine is officially restricted due to the potential for severe additive hypothermia.
• Metamizole is documented as an enzyme inducer, resulting in a reduction in plasma concentrations for co-administered drugs like Cyclosporine, Valproate, and Bupropion.
• The regulatory label notes that Metamizole may inhibit the antiplatelet effect of low-dose Acetylsalicylic acid (ASA), requiring potential administration spacing.
• Product information specifies that Metamizole may potentiate the effects of alcohol.

Connection to the overall interaction profile (2–4 sentences): The regulatory profile establishes that the product’s interaction structure is predominantly defined by pharmacokinetic induction and pharmacodynamic interference. Official labeling classifies these interactions based on severity, ranging from prohibited combinations to constraints that mandate monitoring of drug concentrations or timing separation, as specified by government authorities.

Metamizol Stada, containing the active ingredient metamizole (dipyrone), functions as a non-opioid pyrazolone derivative that exerts its effects via multiple mechanisms, primarily within the central nervous system (CNS). Metamizole is metabolized into the active compounds 4-methylaminoantipyrine ( MAA) and 4-aminoantipyrine ( AA). These metabolites interact with cyclooxygenase (COX) activity, displaying a complex profile that involves the inhibition of COX-1, COX-2, and potentially COX-3. This interaction profile leads to the modulation of prostaglandin synthesis, key lipid mediators in fever and pain signaling pathways. The mechanism also includes the promotion of nitric oxide ( NO) release and potential interaction with central transient receptor potential (TRP) channels. The cumulative effect of these molecular interactions alters hypothalamic activity, resetting the thermoregulatory center and functionally raising the nociceptive threshold in the CNS, thereby modulating core body temperature and the processing of afferent signals.

Instruction Map: How to use Metamizol Stada

This map describes the high-level instructions for administering metamizole (sodium metamizole/dipyrone).

Administration Scope

Instruction Classifications (High-Level)

Connection to the overall use protocol

The use protocol establishes defined numerical constraints for both single and daily dosing across various administration routes, from oral to parenteral. The protocol includes the 6–8 hour waiting period and follows specific preparation and technique rules, particularly for injectable forms, to standardize the medicine's delivery.

Research Evidence / Overview of Studies for Metamizol Stada

The available research provides context for how Metamizol Stada (Sodium Metamizole/Dipyrone) has been studied in several clinical scenarios. This evidence highlights what has been observed so far, what was measured, and where knowledge gaps remain. Research findings describe group patterns and contribute to the broader evidence landscape but do not determine whether an individual will respond similarly.

Evidence for Use in Acute Pain Management

Research has explored the drug's activity for conditions associated with acute pain using Short-term Randomized Controlled Trials (RCTs) and supporting Systematic Reviews. These studies included populations such as adult patients and those in specific post-operative settings. Research examined outcomes related to physical discomfort, primarily focusing on how symptoms are measured using scales for pain intensity and severity. Studies reported measurements of changes in the patients’ perceived discomfort, including patterns observed in the time related to initial symptom change following administration. Research is limited in providing insight into the applicability of these findings to chronic or non-episodic pain.

Evidence for Use in Reducing High Fever

Research has examined the drug's activity for conditions associated with high fever, which is relevant in research contexts involving systemic or functional imbalance. Research was conducted using Short-term RCTs and Systematic Reviews, and studies monitored populations that included both adults and children. The primary outcomes measured in these trials were related to the change in body temperature and the duration of the measurement interval. The findings describe patterns in the time taken to observe a symptom change in temperature, but the certainty remains low regarding sustained fever management.

Evidence for Use in Spasm-Related Symptoms

Studies monitored the drug's activity for conditions characterized by episodic or acute manifestations, specifically focusing on the spasmolytic property in contexts like visceral discomfort. Research examined outcomes related to symptom variability, such as the frequency and intensity of the spasm. The evidence quality varies across studies, and many of the trials used sample sizes that were modest. There is limited information for long-term outcomes, and the drug’s activity outside of acute, severe spasm episodes is not well defined by the existing research structure.

Common questions about Metamizol Stada (FAQ)

Q: What should I do if I miss a dose of Metamizol Stada?

Official guidance indicates patients should adhere to the prescribed dosing schedule if a dose is missed. It is specified that a double dose should not be taken to compensate for the one missed. The product's regulatory summary requires adherence to the 6–8 hour waiting period between doses.

Q: Does Metamizol Stada interact with my regular vitamins or supplements?

Official regulatory documents and the product information primarily detail interactions with other medications (drug-drug interactions). There is no specific information documented in these sources regarding interactions with non-drug products such as standard vitamins or dietary supplements.

Q: Can Metamizol Stada make me feel dizzy or sleepy?

Official product information notes that adverse effects can include somnolence (sleepiness) and vertigo (dizziness). While the frequency of these effects may be classified as Not Known or Uncommon, depending on the specific product SmPC, awareness of these potential effects is part of the product's safety information.

Q: How long after I take the tablet should I expect the pain relief to start working?

Metamizole is recognized as having a rapid onset of action. Regulatory documents note that the main active compounds typically reach their highest concentration in the blood within 1 to 2 hours after oral administration. Furthermore, information related to injectable forms indicates that an effect may be observed within 30 minutes of administration.

Q: Is Metamizol Stada addictive or habit-forming?

Metamizol Stada is classified by regulatory authorities as a non-opioid analgesic. Official safety information and warnings do not include the specific precautions that are typical for medications with a high potential for abuse, dependence, or habit formation.

Q: What are the ingredients in the tablet other than the active one?

The formulation of Metamizol Stada contains the active ingredient, sodium metamizole, along with several inactive components known as excipients. The complete and mandatory list of all ingredients is documented in the specific Summary of Product Characteristics (SmPC) for the product.

Q: Can I drive or operate machinery while taking this medicine?

Official product labeling includes a dedicated warning regarding the ability to drive or use machines. If adverse effects such as dizziness or somnolence (sleepiness) occur, the ability to concentrate and react may be impaired. Patients are advised to use caution when performing tasks that require full attention if these side effects occur.

Q: What country or region is this medication regulated in?

This medicine is regulated across the European Economic Area (EEA), and its marketing authorization (approval for sale) is issued by national regulatory bodies in these countries. The product is manufactured and supplied by Stada Arzneimittel AG, and its regulatory status is tracked by European authorities.

How to Store and Dispose of Metamizol Stada?

This section defines the mandatory, government-documented requirements for protecting and discarding the medicine to ensure product stability and public safety.

All Metamizol Stada formulations must be stored in the original packaging to protect them from environmental degradation. For liquid forms, the container must be closed well after each administration to preserve product quality during the designated in-use period. Proper disposal requires users to utilize established pharmaceutical take-back programs and not dispose of the medicine in common trash or wastewater.